ClinicalTrials.gg
RecruitingNCT05674630TITAN-DEBUpdated Sep 8, 2023

Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons

A Phase 4 interventional study of Magic Touch drug eluting balloon based strategy and Drug-eluting stent-based strategy in Chronic Coronary Syndrome, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Cardiocentro Ticino · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions.

Participants with chronic coronary disease and long coronary stenosis will be randomly assign to be treated either with Magic Touch balloon or drug eluting stent.

Read the detailed description

Patients at coronary angiography who are deemed suitable for PCI are assessed for eligibility. Patients fulfilling all inclusion and no exclusion criteria can be consented for trial participation. After successful lesion preparation, defined as residual stenosis less than 30%, TIMI flow 3 and no major (type C) dissection of target lesion, consented patients will be randomized in a 1:1 ratio to a drug eluting balloon(DEB)-based or standard drug eluting stent(DES)-based strategy and further randomized in a 1:1 fashion, stratified based on DEB vs DES, to undergo invasive follow-up at 6 (±30 days) or 12 (±30 days) months.

02

Conditions studied

  • Chronic Coronary Syndrome

Keywords

  • adult
  • chronic coronary syndrome
  • percutaneous intervention
  • significant de novo coronary lesion
  • FFR≤0.80
  • iFR≤0.89
  • long DES (≥30 mm)
  • coronary lesion
  • drug eluting balloon
  • drug eluting stent
  • Magic Touch drug eluting balloon
03

In context

Lead sponsor

Cardiocentro Ticino is the lead sponsor of 13 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (≥18 years old) with chronic coronary syndrome deemed suitable for PCI
  2. At least one significant de-novo coronary lesion (defined as diameter stenosis > 50% on angiography, with flow limiting features, confirmed with FFR ≤0.80 or iFR ≤0.89 and intended implantation of a long (≥30 mm) DES based on IVUS findings
  3. Written

Exclusion criteria

Exclusion Criteria:

  1. Patients referred to the index procedure for an acute coronary syndrome
  2. Target lesion involving the left main and/or ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery
  3. Severe renal impairment (\<15ml/min/1.73m2) or patient on dialysis treatment
  4. Spontaneous coronary artery dissection (SCAD)
  5. to adenosine administration (e.g. moderate to severe asthma or , heart rate \<50 beats/min and systolic blood pressure \<90 mmHg)
  6. Known pregnancy or breast-feeding patients
  7. \<1 year due to other severe non-cardiac disease
  8. Legally incompetent to provide
  9. Participation in another clinical study with an product
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Magic Touch drug eluting balloon based strategy - 6/12 months invasive follow up

    Patients randomized to DEB-based strategy will receive treatment with DEB (Magic Touch, Concept Medical®) throughout the entire lesion length, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.

    Device: Magic Touch drug eluting balloon based strategy

  • Active comparator
    Drug eluting stent based strategy - 6/12 months invasive follow up

    Percutaneous transluminal coronary angioplasty and drug eluting stent implantation according to local standard of care, including optimization techniques (e.g. post-dilatation) which are left at operators' discretion, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.

    Device: Drug-eluting stent-based strategy

Interventions

  • DeviceMagic Touch drug eluting balloon based strategy

    Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.

  • DeviceDrug-eluting stent-based strategy

    Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.

06

What researchers measure

Primary outcomes

  1. Absolute change of FFR values (ΔFFR)

    Absolute change of fractional flow reserve (FFR) values (ΔFFR) measured at the final assessment immediately after the index PCI and invasive follow-up at 6(±30days) or 12(±30 days) months

    Time frame: At 6(±30days) or 12(±30 days) months after the index PCI

Secondary outcomes

  1. QCA parameter (minimal lumen diameter, MLD, mm) before and after the intervention and at follow-up angiography

    Minimal lumen diameter (MLD,mm) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  2. QCA parameter (maximal diameter stenosis, MaxS, percent) before and after the intervention and at follow-up angiography

    Maximal diameter stenosis (MaxS, percent) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  3. QCA parameter (reference vessel diameter, RVD, mm) before and after the intervention and at follow-up angiography

    Reference vessel diameter (RVD, mm) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  4. QCA parameter (lesion length, LL, mm) before and after the intervention and at follow-up angiography.

    Lesion length (LL, mm) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  5. QFR parameters before and after intervention and at follow-up angiography

    Quantitative Flow Ratio (QFR) parameters before the intervention, immediately after the intervention and at follow-up angiography

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  6. FFR parameters before and after intervention and at follow-up angiography

    Fractional Flow Reserve (FFR) parameters before the intervention, immediately after the intervention and at follow-up angiography

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  7. Minimal lumen diameter (MLD, mm)

    Minimal lumen diameter (MLD, mm) evaluated with intravascular ultrasound (IVUS)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  8. Minimal luminal area (MLA, mm^2)

    Minimal luminal area (MLA, mm\^2) evaluated with intravascular ultrasound (IVUS)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  9. Maximal diameter stenosis (MaxS, percent)

    Maximal diameter stenosis (MaxS, percent) evaluated with intravascular ultrasound (IVUS)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  10. Lumen volume (LV, mm^3)

    Lumen volume (LV, mm\^3) evaluated with intravascular ultrasound (IVUS)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  11. Vessel volume (VV, mm^3)

    Vessel volume (VV, mm\^3) evaluated with intravascular ultrasound (IVUS)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  12. Plaque burden (VV-LV)

    Plaque burden (VV-LV) evaluated with intravascular ultrasound (IVUS)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  13. Late lumen loss (LLL)

    Late lumen loss (LLL) evaluated with intravascular ultrasound (IVUS)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  14. Acute gain

    Variation between pre treatment (T0) and immediately after the treatment (Tf)

    Time frame: pre procedure and immediately after the procedure

  15. Disease progression after index PCI

    Variation between final result of index PCI (Tf) and procedure at 6(±30days) or 12(±30 days) months after the index PCI (Tc)

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI

  16. Target lesion revascularization (TLR) defined as urgent and non-urgent

    Rate of target lesion revascularization (TLR) defined as urgent and non-urgent

    Time frame: 5 years after the index PCI

  17. Target vessel revascularization (TVR), defined as urgent and non-urgent

    Rate of target vessel revascularization (TVR), defined as urgent and non-urgent

    Time frame: 5 years after the index PCI

  18. Target vessel failure (TVF), defined as cardiac death, target-vessel myocardial infarction, and any target lesion revascularization

    Rate of target vessel failure (TVF), defined as cardiac death, target-vessel myocardial infarction, and any target lesion revascularization

    Time frame: 5 years after the index PCI

  19. The individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization)

    Rate of the individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization)

    Time frame: 5 years after the index PCI

  20. Any myocardial infarction

    Rate of any myocardial infarction

    Time frame: 5 years after the index PCI

  21. Stroke

    Rate of stroke

    Time frame: 5 years after the index PCI

  22. Definite or probable stent thrombosis

    Rate of definite or probable stent thrombosis

    Time frame: 5 years after the index PCI

07

Study locations

1 of 1 sites recruiting
  • Marco Valgimigli
    Lugano, 6900, Switzerland
    Recruiting
    • Enrico Frigoli, MD · Contact+410918115111
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Jun 2026, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Jan 6, 2023
StartActual
Feb 21, 2023
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 1, 2030
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05674630
Lead sponsor
Cardiocentro Ticino
Collaborators
University of Bern
Responsible party
Marco Valgimigli (Coordinating Principal Investigator, Cardiocentro Ticino) — Principal investigator
First posted
Jan 6, 2023
Start date
Feb 21, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Sep 8, 2023

Study contacts

Marco Valgimigli, M.D., Ph.D
Contact
marco.valgimigli@eoc.ch
+410918115111
Enrico Frigoli, M.D.
Contact
enrico.frigoli@eoc.ch
Marco Valgimigli, M.D., Ph.D
principal investigator · Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano,

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion